Small Intestine Cancer

Categories: Rare diseases, Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Small Intestine Cancer

MalaCards integrated aliases for Small Intestine Cancer:

Name: Small Intestine Cancer 12 50 14
Neoplasm of Small Intestine 12 69
Small Intestine Neoplasm 12 14
Malignant Neoplasms of the Small Intestine 50
Malignant Tumor of Small Intestine 69
Neoplasm of the Small Intestine 29
Small Intestinal Neoplasm 12
Small Intestine Carcinoma 69
Small Bowel Tumors 50


External Ids:

Disease Ontology 12 DOID:10154 DOID:7505
ICD10 33 C17 C17.9
ICD9CM 35 152.9
NCIt 47 C7523 C4432

Summaries for Small Intestine Cancer

Disease Ontology : 12 An intestinal cancer that is located in the small intestine.

MalaCards based summary : Small Intestine Cancer, also known as neoplasm of small intestine, is related to small intestine cancer, childhood and gallbladder cancer. An important gene associated with Small Intestine Cancer is SST (Somatostatin), and among its related pathways/superpathways are DNA Damage and Endometrial cancer. The drugs Oxaliplatin and Adalimumab have been mentioned in the context of this disorder. Affiliated tissues include small intestine, liver and colon, and related phenotypes are Synthetic lethal with vaccinia virus (VACV) infection and cellular

Wikipedia : 72 In oncology, small intestine cancer, also small bowel cancer and cancer of the small bowel, is a cancer... more...

Related Diseases for Small Intestine Cancer

Diseases in the Small Intestine Cancer family:

Intestine Carcinoma in Situ

Diseases related to Small Intestine Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 163)
id Related Disease Score Top Affiliating Genes
1 small intestine cancer, childhood 33.9 ENO2 KRT20
2 gallbladder cancer 27.4 CCND1 CDX2 KIT KRAS MLH1 MSH2
3 small intestinal adenocarcinoma 10.9
4 situs inversus 10.8 MUC2 MUC6
5 limb ischemia 10.8 KRAS SST
6 urinary system disease 10.8 MUC2 MUC6
7 bestiality 10.7 MUC2 MUC6
8 small intestine carcinoid neuroendocrine tumor 10.7
9 duodenum cancer 10.7
10 ileum cancer 10.7
11 ascending colon cancer 10.7 KRT20 MUC2
12 pemphigus foliaceus 10.7 ENO2 SST
13 ampulla of vater squamous cell carcinoma 10.7 KRT20 MUC6
14 endocervical adenocarcinoma 10.7 ENO2 SST
15 liver lymphoma 10.7 KRAS SST
16 trigonitis 10.7 KIT MUC6
17 cervical keratinizing squamous cell carcinoma 10.7 ENO2 SST
18 morbid obesity 10.7 ENO2 MUC6
19 familial renal oncocytoma 10.7 ENO2 KRT20
20 combined thymoma 10.6 CD79A SST
21 clear cell squamous cell skin carcinoma 10.6 KIT KRT20
22 glomus tumor 10.6 ENO2 KIT
23 gorlin bushkell jensen syndrome 10.6 ENO2 KRT20
24 gastric papillary adenocarcinoma 10.6 KIT KRAS
25 acute pre-b-cell lymphoblastic leukemia 10.6 KIT KRAS
26 retroperitoneal leiomyosarcoma 10.6 ENO2 KIT
27 mucinous adenocarcinoma 10.5 KIT KRT20
28 bladder benign neoplasm 10.5 ENO2 KRAS
29 hereditary persistence of fetal hemoglobin, klf1-related 10.5 MLH1 MUC6
30 testicular trophoblastic tumor 10.5 KRT20 MUC2 MUC6
31 epilepsy with generalized tonic-clonic seizures 10.5 ENO2 MUC6 SST
32 choriocarcinoma 10.5 KRT20 MUC2 MUC6
33 demyelinating disease 10.5 ENO2 KIT
34 struma ovarii 10.5 KRT20 MUC2 MUC6
35 brain stem infarction 10.5 ENO2 KIT
36 adie pupil 10.5 CD79A SST
37 thymus small cell carcinoma 10.5 ENO2 KIT
38 malignant biphasic mesothelioma 10.5 MUC2 MUC6
39 breast adenoid cystic carcinoma 10.5 KIT KRAS
40 bile duct clear cell adenocarcinoma 10.4 CDX2 MUC2
41 ovarian mucinous adenocarcinoma 10.4 KRT20 MUC2
42 papilloma 10.4 MLH1 MUC6
43 sensory system cancer 10.4 CDX2 KRT20
44 lung occult small cell carcinoma 10.4 CDX2 KRT20
45 fibroepithelial polyp of urethra 10.4 CDX2 KRT20
46 encephalitozoonosis 10.4 ENO2 KIT
47 endocrine gland cancer 10.4 ENO2 KRT20 SST
48 vestibular gland benign neoplasm 10.4 ENO2 KIT SST
49 bile duct mucinous adenocarcinoma 10.4 CDX2 KRAS
50 cowden syndrome 3 10.4 ENO2 SST

Comorbidity relations with Small Intestine Cancer via Phenotypic Disease Network (PDN):

Colorectal Cancer Deficiency Anemia
Intestinal Obstruction

Graphical network of the top 20 diseases related to Small Intestine Cancer:

Diseases related to Small Intestine Cancer

Symptoms & Phenotypes for Small Intestine Cancer

GenomeRNAi Phenotypes related to Small Intestine Cancer according to GeneCards Suite gene sharing:

id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with vaccinia virus (VACV) infection GR00362-A 9.02 CD79A CDX2 KRAS MLH1 MSH6

MGI Mouse Phenotypes related to Small Intestine Cancer:

id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.96 CCND1 CD79A CDX2 ENO2 KIT KRAS
2 digestive/alimentary MP:0005381 9.76 CDX2 KIT KRAS MLH1 MSH2 MUC2
3 homeostasis/metabolism MP:0005376 9.65 CCND1 CD79A CDX2 KIT KRAS MLH1
4 neoplasm MP:0002006 9.28 CCND1 CD79A CDX2 KIT KRAS MLH1

Drugs & Therapeutics for Small Intestine Cancer

Drugs for Small Intestine Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 314)
id Name Status Phase Clinical Trials Cas Number PubChem Id
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 5310940 9887054 43805 6857599
Adalimumab Approved Phase 4 331731-18-1 16219006
3 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
4 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
5 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
6 Cola Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613 2171
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
Capecitabine Approved, Investigational Phase 2, Phase 3,Phase 1 154361-50-9 60953
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
Ondansetron Approved Phase 3 99614-02-5 4595
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
Guaifenesin Approved, Vet_approved Phase 3,Phase 2 93-14-1 3516
Morphine Approved, Investigational Phase 3 57-27-2 5288826
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
Ofloxacin Approved Phase 3 82419-36-1 4583
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
Levoleucovorin Approved Phase 3,Phase 1 68538-85-2
Pancrelipase Approved Phase 3,Phase 2,Phase 1 53608-75-6
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
24 lanreotide Approved Phase 3 108736-35-2
Somatostatin Approved Phase 3,Phase 1 38916-34-6, 51110-01-1 53481605
Octreotide Approved, Investigational Phase 3,Phase 2,Phase 1 83150-76-9 383414 6400441
Histamine Approved, Investigational Phase 3,Phase 1 75614-87-8, 51-45-6 774
Ranitidine Approved Phase 3,Phase 2 66357-59-3, 66357-35-5 3001055
Cyproheptadine Approved Phase 3 129-03-3 2913
Pantoprazole Approved Phase 3 102625-70-7 4679
31 Orange Approved, Nutraceutical Phase 3
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
33 Pancreatic Polypeptide Investigational Phase 3,Phase 2,Phase 1 59763-91-6
34 Amoxicillin-Potassium Clavulanate Combination Phase 3
35 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
36 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
37 Anti-Infective Agents Phase 3,Phase 2,Phase 1
38 Antitubercular Agents Phase 3
39 beta-Lactamase Inhibitors Phase 3
40 Clavulanic Acid Phase 3
41 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
42 Cytochrome P-450 Enzyme Inhibitors Phase 3
43 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
44 Antimetabolites Phase 2, Phase 3, Phase 1
45 Antimetabolites, Antineoplastic Phase 2, Phase 3, Phase 1
46 Dermatologic Agents Phase 3,Phase 2,Phase 1
47 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
48 glucocorticoids Phase 3,Phase 2,Phase 1
49 Hormone Antagonists Phase 3,Phase 2,Phase 1
50 Hormones Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 269)

id Name Status NCT ID Phase Drugs
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
2 Endoscopic Detection of Dysplasia in Crohn 's Disease Patient Completed NCT01180452 Phase 4
3 Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing Completed NCT01174186 Phase 4 Adalimumab
4 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
5 Roux-en-Y Versus Billroth II Reconstruction After Subtotal Gastrectomy in Gastric Cancer Comorbid With Type II Diabetes Unknown status NCT01528059 Phase 2, Phase 3
6 A Trial of High Intensity Versus Low Intensity Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Unknown status NCT01064999 Phase 2, Phase 3 Oxaliplatin;Capecitabine
7 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
8 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
9 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
10 Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy Completed NCT00003600 Phase 3
11 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
12 Bioresorbable Membrane to Reduce Postoperative Small Bowel Obstruction Completed NCT00529412 Phase 3
13 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3 dexamethasone;ondansetron
14 Surgery Followed by Radiation Therapy and Chemotherapy in Treating Patients With Cancer of the Pancreas Completed NCT00003049 Phase 3 fluorouracil;leucovorin calcium
15 Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00850772 Phase 3
16 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
17 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
18 Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis Completed NCT00216372 Phase 3 Lanreotide (microparticle formulation)
19 Tomotherapy vs Conventional Radiation for Adjuvant Pelvic RT in Ca Cervix Recruiting NCT01279135 Phase 3
20 Surgical Complications Related to Primary or Interval Debulking in Ovarian Neoplasm Recruiting NCT01461850 Phase 3
21 A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours Active, not recruiting NCT01578239 Phase 3 Octreotide LAR;177Lu-DOTA0-Tyr3-Octreotate
22 Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel Adenocarcinoma Not yet recruiting NCT02502370 Phase 3 observation alone;LV5FU2;FOLFOX
23 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
24 Esophageal Metaplasia Using a Novel Antibody: Reversibility by Proton Pump Inhibitor Terminated NCT00161200 Phase 3 Ranitidine & Pantoprazole
25 Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis Withdrawn NCT00026468 Phase 2, Phase 3 exisulind
26 High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma Unknown status NCT00669812 Phase 2 carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;melphalan;methotrexate;prednisolone;vincristine sulfate
27 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
28 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Unknown status NCT00621036 Phase 2 methotrexate;thiotepa
29 Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer Unknown status NCT00019474 Phase 2 fluorouracil;hydroxyurea
30 The Impact of Patient Positioning and Use of Belly Board on Small Bowel and Urinary Bladder Volume Irradiated in Patients Receiving Radiotherapy for Rectal Cancer: A Prospective Phase II Study Unknown status NCT01142713 Phase 2
31 Phase II Study of Preoperative IMRT Combined With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer Unknown status NCT01871363 Phase 2
32 Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer Completed NCT00433550 Phase 2 capecitabine;irinotecan hydrochloride;oxaliplatin
33 Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma Completed NCT00006039 Phase 2
34 Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma Completed NCT00079261 Phase 2 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;gemcitabine hydrochloride;prednisone;vincristine sulfate
35 Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma Completed NCT00004066 Phase 2 docetaxel;gemcitabine hydrochloride
36 Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas Completed NCT01730586 Phase 2 Abraxane
37 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
38 Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas Completed NCT00005874 Phase 2 rubitecan
39 Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction Completed NCT00004911 Phase 1, Phase 2
40 Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction Completed NCT00004910 Phase 1, Phase 2
41 Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer Completed NCT00005049 Phase 2 carboplatin;cisplatin;floxuridine
42 Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery Completed NCT00004895 Phase 2 octreotide acetate
43 Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer Completed NCT00903396 Phase 2 palonosetron hydrochloride
44 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
45 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
46 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
47 Capecitabine and Oxaliplatin in Adenocarcinoma of the Small Bowel and Ampulla of Vater Completed NCT00354887 Phase 2 Capecitabine;Oxaliplatin
48 Non-Ablative Allo HSCT For Hematologic Malignancies or SAA Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
49 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00005804 Phase 2 cyclophosphamide
50 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer Completed NCT00589563 Phase 2 cyclophosphamide;etoposide;fludarabine phosphate;melphalan;methotrexate;sirolimus;tacrolimus

Search NIH Clinical Center for Small Intestine Cancer

Genetic Tests for Small Intestine Cancer

Genetic tests related to Small Intestine Cancer:

id Genetic test Affiliating Genes
1 Neoplasm of the Small Intestine 29

Anatomical Context for Small Intestine Cancer

MalaCards organs/tissues related to Small Intestine Cancer:

Small Intestine, Liver, Colon, Bone, T Cells, B Cells, Bone Marrow

Publications for Small Intestine Cancer

Articles related to Small Intestine Cancer:

id Title Authors Year
Hemorrhagic small intestine cancer with solitary pulmonary metastasis initially presented as suspected primary lung cancer: an autopsy report. ( 18432067 )
Associations between small intestine cancer and other primary cancers: an international population-based study. ( 16003748 )
Small Intestine Cancer Treatment (PDQAr): Patient Version ( 26389461 )
Small Intestine Cancer Treatment (PDQAr): Health Professional Version ( 26889555 )
Small Intestine Cancer Treatment (PDQAr): Patient Version ( 27390834 )
Small Intestine Cancer Treatment (PDQAr): Health Professional Version ( 26389423 )
Risk factors for small intestine cancer. ( 8481495 )

Variations for Small Intestine Cancer

Expression for Small Intestine Cancer

Search GEO for disease gene expression data for Small Intestine Cancer.

Pathways for Small Intestine Cancer

GO Terms for Small Intestine Cancer

Cellular components related to Small Intestine Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 MutSalpha complex GO:0032301 8.62 MSH2 MSH6

Biological processes related to Small Intestine Cancer according to GeneCards Suite gene sharing:

(show all 16)
id Name GO ID Score Top Affiliating Genes
1 cellular response to DNA damage stimulus GO:0006974 9.86 CCND1 MLH1 MSH2 MSH6
2 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.71 KRAS MUC2 MUC6
3 response to X-ray GO:0010165 9.55 CCND1 MSH2
4 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.54 MLH1 MSH2 MSH6
5 determination of adult lifespan GO:0008340 9.52 MSH2 MSH6
6 maintenance of gastrointestinal epithelium GO:0030277 9.51 MUC2 MUC6
7 mismatch repair GO:0006298 9.5 MLH1 MSH2 MSH6
8 positive regulation of isotype switching to IgG isotypes GO:0048304 9.49 MLH1 MSH2
9 negative regulation of DNA recombination GO:0045910 9.48 MSH2 MSH6
10 positive regulation of helicase activity GO:0051096 9.46 MSH2 MSH6
11 maintenance of DNA repeat elements GO:0043570 9.43 MSH2 MSH6
12 positive regulation of isotype switching to IgA isotypes GO:0048298 9.4 MLH1 MSH2
13 somatic hypermutation of immunoglobulin genes GO:0016446 9.33 MLH1 MSH2 MSH6
14 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.26 MLH1 MSH2
15 isotype switching GO:0045190 9.13 MLH1 MSH2 MSH6
16 somatic recombination of immunoglobulin gene segments GO:0016447 8.8 MLH1 MSH2 MSH6

Molecular functions related to Small Intestine Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 double-stranded DNA binding GO:0003690 9.58 CDX2 MSH2 MSH6
2 four-way junction DNA binding GO:0000400 9.43 MSH2 MSH6
3 MutLalpha complex binding GO:0032405 9.37 MSH2 MSH6
4 oxidized purine DNA binding GO:0032357 9.32 MSH2 MSH6
5 single guanine insertion binding GO:0032142 9.26 MSH2 MSH6
6 single thymine insertion binding GO:0032143 9.16 MSH2 MSH6
7 mismatched DNA binding GO:0030983 9.13 MLH1 MSH2 MSH6
8 guanine/thymine mispair binding GO:0032137 8.8 MLH1 MSH2 MSH6

Sources for Small Intestine Cancer

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
52 Novoseek
55 OMIM via Orphanet
59 PubMed
66 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....